Projects and Grants per year
Personal profile
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
Residency, Medstar Good Samaritan Hospital/Union Memorial - Baltimore
2016
Doctor of Medicine, University of Medicine, Mandalay, Myanmar
2007
Fingerprint
Dive into the research topics where Zin Myint is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration from the last 5 years on country level. Dive into details by clicking on the dots.
-
24-GU-84-MSD (003-00):A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Next-Generation Hormonal Ag
Myint, Z. (PI)
Merck Sharp & Dohme Corporation
4/29/24 → 4/29/26
Project: Research project
-
24-GU-85-MSD (004-00): A Phase 3, Randomized, Open-Label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with
Myint, Z. (PI)
Merck Sharp & Dohme Corporation
4/28/24 → 4/28/26
Project: Research project
-
Personnel Costs: The Experimental Therapeutics Clinical Trials Network
Arnold, S. (PI), Gabriel, G. (CoI), Myint, Z. (CoI), Chauhan, A. (Former CoI), Kolesar, J. (Former CoI) & Kunos, C. (Former CoI)
3/1/24 → 2/28/26
Project: Research project
-
MCC-22-GU-80: Phase II Study of Pembrolizumab in Combination with Radiation with or without Olaparib in Localized High-risk Prostate Cancer
Myint, Z. (PI)
Merck Sharp & Dohme Corporation
10/12/22 → 9/18/25
Project: Research project
-
A Phase 3, Randomized, Controlled, Multicenter, Open-Label Study to Compare Tivozanib in Combination with Nivolumab to Tivozanib Monotherapy in Subjects with Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy
Myint, Z. (PI)
AVEO Pharmaceuticals Incorporated
5/25/22 → 10/30/25
Project: Research project
-
Hematological adverse events in the management of glioblastoma
Garcia, C. R., Myint, Z. W., Jayswal, R., Wang, C., Morgan, R. M., Butts, A. R., Weiss, H. L. & Villano, J. L., Jan 2022, In: Journal of Neuro-Oncology. 156, 1, p. 153-161 9 p.Research output: Contribution to journal › Article › peer-review
-
Priming immunotherapy with radiotherapy (RT) in advanced non-small cell lung cancer (NSCLC) and head and neck squamous cell cancer (HNSCC): Interim analysis of phase II clinical trial.
Jacob, A., Kreimer, A., Wei, J., Wu, J., Corum, L., Reusch, E., Woodward, J., Cohen, D., Bondada, S., Adams, V. R., Morgan, R., McGarry, R. C., St Clair, W. H., Kudrimoti, M. R., Myint, Z., Arnold, S. M. & Villano, J. L., May 20 2021, In: Journal of Clinical Oncology.Research output: Contribution to journal › Article
-
Management of Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia: Review and a Single Center Experience
Myint, Z. W., McCormick, J., Chauhan, A., Behrens, E. & Anthony, L. B., Oct 1 2018, In: Lung. 196, 5, p. 577-581 5 p.Research output: Contribution to journal › Review article › peer-review
18 Scopus citations